Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA
Study results suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors.
This study's information can inform policy issues, particularly the collection of patient-reported outcome data and its use in clinical practice.
Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.
Study findings suggest that PSA density has a better accuracy for detecting prostate cancer compared with PSA higher than 4 ng/mL.
The change was initiated by additional data demonstrating a decreased mortality risk associated with PSA screening.
More Articles by Andrea S. Blevins Primeau, PhD, MBA
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL
- Cancer-specific Reference Values Established for PROMIS Domains
- 99mTc-MIBI SPECT/CT Differentiates Between Benign, Malignant Kidney Tumors
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer